# Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

> **NCT01764633** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 27564 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **BIOLOGICAL:** Evolocumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01764633
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-08
- **Primary completion:** 2016-11-11
- **Final completion:** 2016-11-11
- **Target enrollment:** 27564 (ACTUAL)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01764633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01764633, "Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01764633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*